CA2782796A1 - Compositions and methods for the treatment of angiogenesis-related eye diseases - Google Patents

Compositions and methods for the treatment of angiogenesis-related eye diseases Download PDF

Info

Publication number
CA2782796A1
CA2782796A1 CA2782796A CA2782796A CA2782796A1 CA 2782796 A1 CA2782796 A1 CA 2782796A1 CA 2782796 A CA2782796 A CA 2782796A CA 2782796 A CA2782796 A CA 2782796A CA 2782796 A1 CA2782796 A1 CA 2782796A1
Authority
CA
Canada
Prior art keywords
variant
rhodostomin
seq
rhodostomin variant
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2782796A
Other languages
English (en)
French (fr)
Inventor
Woei-Jer Chuang
Wen-Mei Fu
Yen-Lun Huang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
National Taiwan University NTU
National Cheng Kung University NCKU
Original Assignee
National Taiwan University NTU
National Cheng Kung University NCKU
TWi Biotechnology Inc
DCB USA LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by National Taiwan University NTU, National Cheng Kung University NCKU, TWi Biotechnology Inc, DCB USA LLC filed Critical National Taiwan University NTU
Publication of CA2782796A1 publication Critical patent/CA2782796A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
CA2782796A 2009-12-23 2010-12-22 Compositions and methods for the treatment of angiogenesis-related eye diseases Abandoned CA2782796A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US28962409P 2009-12-23 2009-12-23
US61/289,624 2009-12-23
PCT/US2010/061738 WO2011079175A1 (en) 2009-12-23 2010-12-22 Compositions and methods for the treatment of angiogenesis-related eye diseases

Publications (1)

Publication Number Publication Date
CA2782796A1 true CA2782796A1 (en) 2011-06-30

Family

ID=44151942

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2782796A Abandoned CA2782796A1 (en) 2009-12-23 2010-12-22 Compositions and methods for the treatment of angiogenesis-related eye diseases

Country Status (14)

Country Link
US (1) US9044436B2 (enExample)
EP (1) EP2515926A4 (enExample)
JP (1) JP5739908B2 (enExample)
KR (1) KR20120130752A (enExample)
CN (1) CN102883738A (enExample)
AR (1) AR079706A1 (enExample)
AU (1) AU2010336475A1 (enExample)
BR (1) BR112012015188A8 (enExample)
CA (1) CA2782796A1 (enExample)
MX (1) MX2012007416A (enExample)
NZ (1) NZ600544A (enExample)
RU (1) RU2012131251A (enExample)
TW (1) TWI581801B (enExample)
WO (1) WO2011079175A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010092135A2 (en) 2009-02-11 2010-08-19 Novozymes Biopharma Uk Ltd. Albumin variants and conjugates
NZ597580A (en) * 2009-07-20 2013-11-29 Univ Nat Taiwan Polypeptides selective for alpha.v.beta.3 integrin conjugated with a variant of human serum albumin (hsa) and pharmaceutical uses thereof
CN102741280B (zh) 2009-10-30 2015-12-02 诺维信生物制药丹麦公司 白蛋白变体
CN106977608A (zh) 2010-04-09 2017-07-25 阿尔布麦狄克斯公司 白蛋白衍生物和变体
HK1200842A1 (en) 2011-11-18 2015-08-14 Albumedix Ltd Proteins with improved half-life and other properties
MX2014010278A (es) 2012-03-16 2015-03-05 Novozymes Biopharma Dk As Variantes de albumina.
WO2014072481A1 (en) 2012-11-08 2014-05-15 Novozymes Biopharma Dk A/S Albumin variants
WO2015147616A1 (ko) * 2014-03-28 2015-10-01 연세대학교 산학협력단 Rgd 모티프를 포함하는 펩타이드 또는 단백질을 포함하는 신경염증 예방, 억제 또는 치료용 조성물
EP3182988A4 (en) * 2014-08-22 2018-05-23 National Cheng Kung University Disintegrin variants and pharmaceutical uses thereof
ES2836426T3 (es) * 2014-12-31 2021-06-25 Huons Co Ltd Composición, que contiene péptido que contiene motivo RGD o fragmento de éste, para aliviar las arrugas de la piel
CN108430489B (zh) * 2015-06-28 2022-03-25 新源生物科技股份有限公司 用于抑制血管新生的融合蛋白
WO2017029407A1 (en) 2015-08-20 2017-02-23 Albumedix A/S Albumin variants and conjugates
US12304037B2 (en) 2021-11-03 2025-05-20 Aob Products Company Torque driver
US11723955B1 (en) 2022-05-13 2023-08-15 Allgenesis Biotherapeutics Inc. VEGFR fusion protein pharmaceutical composition
KR20250021281A (ko) 2023-08-04 2025-02-12 주식회사 넥스세라 콜라겐 타입 i 및 색소 상피성 인자 펩타이드를 유효성분으로 포함하는 안구 혈관신생 질환의 예방 또는 치료용 점안제 조성물
CN121666229A (zh) 2023-08-04 2026-03-13 (株)来时协乐 包含i型胶原蛋白和色素上皮衍生因子肽作为活性成分的、用于预防或治疗新生血管性眼病的滴眼液组合物

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
DE3675588D1 (de) 1985-06-19 1990-12-20 Ajinomoto Kk Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist.
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US6552170B1 (en) 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
US6710030B1 (en) 1993-10-22 2004-03-23 University Of Southern California Contortrostain (CN) and methods for its use in preventing metastasis and other conditions
US5659018A (en) * 1995-08-01 1997-08-19 Genetics Institute, Inc. Mocarhagin, a cobra venom protease, and therapeutic uses thereof
AU2002339862A1 (en) * 2001-09-04 2003-05-26 Aventis Pharmaceuticals Inc. Abrogen polypeptides, nucleic acids encoding them and methods for using them to inhibit angiogenesis
EP1534718A4 (en) 2002-06-07 2006-06-07 Wisconsin Alumni Res Found CHEMICAL SYNTHESIS OF REAGENTS FOR PEPTIDE COUPLING
US20070025957A1 (en) * 2005-04-29 2007-02-01 Rosenblum Michael G Vascular targeting of ocular neovascularization
US7943728B2 (en) * 2006-12-26 2011-05-17 National Cheng Kung University Disintegrin variants and their use in treating osteoporosis-induced bone loss and angiogenesis-related diseases
NZ597580A (en) * 2009-07-20 2013-11-29 Univ Nat Taiwan Polypeptides selective for alpha.v.beta.3 integrin conjugated with a variant of human serum albumin (hsa) and pharmaceutical uses thereof

Also Published As

Publication number Publication date
MX2012007416A (es) 2012-07-23
NZ600544A (en) 2014-06-27
AU2010336475A1 (en) 2012-06-14
RU2012131251A (ru) 2014-01-27
JP5739908B2 (ja) 2015-06-24
EP2515926A4 (en) 2013-10-09
US20110152192A1 (en) 2011-06-23
TWI581801B (zh) 2017-05-11
BR112012015188A2 (pt) 2016-04-05
CN102883738A (zh) 2013-01-16
AR079706A1 (es) 2012-02-15
JP2013515739A (ja) 2013-05-09
BR112012015188A8 (pt) 2016-08-09
TW201138801A (en) 2011-11-16
WO2011079175A1 (en) 2011-06-30
EP2515926A1 (en) 2012-10-31
US9044436B2 (en) 2015-06-02
KR20120130752A (ko) 2012-12-03

Similar Documents

Publication Publication Date Title
US9044436B2 (en) Compositions and methods for the treatment of angiogenesis-related eye diseases
US7531173B2 (en) Ophthalmic composition of a VEGF antagonist
JP2020203889A (ja) 抗体製剤
US20230105611A1 (en) Combination therapy with cgrp antagonists and clostridial derivatives
CN114099664B (zh) 一种基于Treg细胞外泌体的靶向协同药物体系及其制备方法
JP2024510480A (ja) 融合タンパク質の新規製剤
AU2020414152B2 (en) Application of fusion protein in treating age-related macular degeneration
JP7650074B2 (ja) 眼疾患を治療するための組成物及び方法
WO2022183418A1 (zh) 抗vegf抗体制剂
KR101467841B1 (ko) 트롬빈 유래 펩타이드를 포함하는 망막증 또는 녹내장 치료용 조성물
JP6944463B2 (ja) 眼疾患の治療のための組成物及び方法
US20250339491A1 (en) Monomeric annexin a5 for use in the treatment of macular oedema or retinal vein occlusion
EP4429693B1 (en) Monomeric annexin a5 for use in the treatment of macular oedema or retinal vein occlusion
HK40115628A (en) Monomeric annexin a5 for use in the treatment of macular oedema or retinal vein occlusion
HK40115628B (en) Monomeric annexin a5 for use in the treatment of macular oedema or retinal vein occlusion

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20161222